The 1 analysts offering 12-month price forecasts for Rubius Therapeutics Inc have a median target of 3.00, with a high estimate of 3.00 and a low estimate of 3.00. The median estimate represents a +1,021.50% increase from the last price of 0.27.
The current consensus among 1 polled investment analysts is to Hold stock in Rubius Therapeutics Inc. This rating has held steady since November, when it was unchanged from a Hold rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.42
Reporting Date Nov 16
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.